Drug Trial Radar · NCT00883116
A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer
Last checked: Nov 20, 2026Latest source record: Mar 9, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
551
Actual
Start
Aug 2009
Primary completion
Jun 2012
Study completion Feb 2014
Sponsor
- Lead sponsor
- R-PharmIndustry
- Sponsor type
- Industry
- First posted
- Apr 17, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to investigate whether administration of ixabepilone results in superior outcome as assessed by overall survival compared with that achieved with standard chemotherapy (paclitaxel or doxorubicin) in women with advanced endometrial cancer that has progressed following first-line chemotherapy.
Conditions
- Endometrial Cancer
Interventions
IxabepiloneDrug
DoxorubicinDrug
PaclitaxelDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Date of randomization to date of death or last date censored to up to approximately 26 months
Locations
93 sites in 19 countries. Site status is shown where the registry gives one.
University Of South Alabama
Mobile, Alabama
Rocky Mountain Gynecologic Oncology
Englewood, Colorado
Peter E. Schwartz, Md
New Haven, Connecticut
Hematology Oncology, P.C.
Stamford, Connecticut
Gynecologic Oncology Assoc.,Inc
Hollywood, Florida
Florida Hospital Cancer Institute
Orlando, Florida
Sarasota Memorial Health Care System
Sarasota, Florida
H. Lee Moffitt Cancer Center
Tampa, Florida
Georgia Health Science University
Augusta, Georgia
Sudarshan K. Sharma, Md
Hinsdale, Illinois
Central Dupage Hospital Cancer Center
Warrenville, Illinois
St. Vincent Hospital And Health Care Center, Inc.
Indianapolis, Indiana
Hematology And Oncology Specialists, Llc
Marrero, Louisiana
Women'S Health Specialists
Rockville, Maryland
Sparrow Regional Cancer Center
Lansing, Michigan
University Of Minnesota
Minneapolis, Minnesota
Saint Dominic's Gynecologic Oncology
Jackson, Mississippi
Matthew A Powell, Md
St Louis, Missouri
Blumenthal Cancer Center
Charlotte, North Carolina
Duke University Medical Center
Durham, North Carolina
Peggy And Charles Stephenson Oklahoma Cancer Center
Oklahoma City, Oklahoma
Tulsa Cancer Institute
Tulsa, Oklahoma
Pennsylvania Oncology Hematology Associates
Philadelphia, Pennsylvania
Magee-Womens Hospital Of Upmc Laboratory
Pittsburgh, Pennsylvania
Women & Infants Hospital Of Ri
Providence, Rhode Island
Cancer Centers Of The Carolinas
Greenville, South Carolina
Tennessee Gynecologic Oncology Group, Llc
Chattanooga, Tennessee
University Of Virginia
Charlottesville, Virginia
Local Institution
La Rioja, La Rioja Province, Argentina
Local Institution
Salta, Salta Province, Argentina
Local Institution
Rosario, Santa Fe Province, Argentina
Local Institution
Milton, Queensland, Australia
Local Institution
East Bentleigh, Victoria, Australia
Local Institution
Ghent, Belgium
Local Institution
Leuven, Belgium
Local Institution
Porto Alegre, Rio Grande do Sul, Brazil
Local Institution
Barretos, São Paulo, Brazil
Local Institution
Jaú, São Paulo, Brazil
Local Institution
São Paulo, São Paulo, Brazil
Local Institution
Calgary, Alberta, Canada
Showing 40 of 93 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.